BTK and B-cell chronic lymphocytic leukemia: Despite the introduction of new effective targeted therapies such as BTK (e.g. ibrutinib, acalabrutinib) and BCL‐2 (e.g. venetoclax) inhibitors, a majority of patients eventually relapse, so CLL still remains an incurable disease.2, 3